Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1

Journal of Infectious Diseases

Volumn 179, Issue 5, 1999, Pages 1116-1123

  Murphy, Robert L ^a,b   Sommadossi, Jean Pierre ^a,b   Lamson, Michael ^a,b   Hall, David B ^a,b   Myers, Maureen ^a,b,c   Dusek, Alex ^a,b,d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^c Novirio Pharmaceuticals   (United States)

^d Trimeris Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INDINAVIR; NEVIRAPINE; VIRUS RNA;

ADULT; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; AREA UNDER CURVE; CD4 LYMPHOCYTE COUNT; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; MALE; MIDDLE AGED; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL;

EID: 0033046403     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314703     Document Type: Article

References (22)

1. 1. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society - USA Panel. JAMA 1998;280:78-86.
2. 2. Gulick R, Mellors J, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
3. 3. Powderly W, Sension M, Conant M, Stein A, Clendeninn N. The efficacy of Viracept (nelfinavir mesylate, NLF) in pivotal phase II/III double-blind, randomized controlled trials as monotherapy and in combination with d4T or AZT/3TC [abstract 370]. In: 4th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Washington, DC). Alexandria, VA: Infectious Diseases Society of America, 1997:132.
4. 4. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
5. 5. Montaner JSG, Reiss P, Cooper D, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HTV-infected patients: the INCAS trial. JAMA 1998;279:930-7.
6. 6. Clendeninn N, Quart B, Anderson R, Knowles, Chang Y. Analysis of long-term virologie data from the Viracept (nelfinavir, NFV) 511 protocol using 3 HIV-RNA assays [abstract 372]. In: 5th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Alexandria, VA). Alexandria, VA: Infectious Diseases Society of America, 1998:148.
7. 7. Sommadossi JPS. HIV protease inhibitors: pharmacologic and metabolic distinctions. AIDS 1999 (in press).
8. 8. Murphy RL, Montaner J. Nevirapine: a review of its development, pharmacological profile and potential for clinical use. Exp Opin Invest Drugs 1996;5:1183-99.
9. 9. Cheeseman SH, Hattox SE, McLaughlin M, et al. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. Antimicrob Agents Chemother 1993;37:178-82.
10. 10. Havlir D, Cheeseman SH, McLaughlin M, et al. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J Infect Dis 1995; 171:537-45.
11. 11. Squires KE, Saag MS, Teppler H, et al. Phase I studies of L-735,524, an HIV protease inhibitor: pharmacokinetics, tolerability and short-term antiviral activity. Clin Res 1994;42:280A.
12. 12. Kim BM, Vacca JP, Guare JP, Hanifin CM, Michelson, SR, Darke PL. A new hydroxyethylamine class of HIV-1 protease inhibitors with high antiviral potency and oral bioavailability. Bioorg Med Chem Lett 1994; 4: 2273-8.
13. 13. Balani SK, Woolf EJ, Hoagland VL, et al. Disposition of indinavir, a potent HIV-1 protease inhibitor, after an oral dose in human. Drug Metab Dispos 1996;24:1389-94.
14. 14. Burger DM, de Graaff M, Wuis EW, Koopmans PP, Hekster YA. Determination of indinavir, an HIV-protease inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1997;703:235-41.
15. 15. Zhou XJ, Sheiner LB, D'Quila RT, et al. Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus infected patients. Antimicrob Agents Chemother 1999;43:121-8.
16. 16. Harris M, Durakovic C, Rae S, et al. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy. J Infect Dis 1998;177:1514-20.
17. 17. Harris M, Whaley M, DeWet JJ, et al. 1 year follow-up of HIV patients treated with nevirapine, indinavir, and lamivudine in combination [abstract 429a]. In: 5th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Alexandria, VA). Alexandria, VA: Infectious Diseases Society of America, 1998:160.
18. 18. Daly AR, Idle JR. Genetics: animal and human cytochrome P450 polymorphism. In: Schenkman JB, Grein H, eds. Cytochrome P450. Berlin: Springer, 1993:433-46.
19. 19. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL. A 24-week open-label phase T/II evaluation of the HIV protease inhibitor MK-639 (indinavir). AIDS 1996;10:485-92.
20. 20. Drusano GL, Stein DS. Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor indinavir. Antimicrob Agents Chemother 1998;42:358-61.
21. 21. Acosta EP, Henry K, Weller D, et al. Indinavir pharmacokinetics and relationships between exposure and antiviral effect [abstract A-15]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington, DC: American Society for Microbiology, 1997:3.
22. 22. Chodakawitz J, Deutsch P, Leavitt R, et al. Relationships between indinavir (IDV) pharmacokinetics and antiviral activity in phase I/II trials [abstract 42266]. In: Abstracts of the XII World AIDS Conference (Geneva). Stockholm: International AIDS Society, 1998:826.